TRIPS Waiver

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

Blog: USTR: Don’t let opposition to TRIPS waiver expansion stop here, 12/6/2022

Webinar: Unpacking the Proposed TRIPS Waiver Expansion: A Conversation with Gary Locke, 12/1/2022

Blog: On TRIPS waiver extension, America must stand up — not stand by, 11/9/2022

Blog: Don’t suspend IP protections on Covid-19 diagnostics and therapeutics, 10/31/2022

Scroll to Top